( en | de | ru )

 

Disambiguation of "Pfreundschuh, Michael"

Author of the publication

copydeleteadd this publication to your clipboard
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era

, , , , , , and . Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 (14): 2373–2380 (2010)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

Michael Pfreundschuh

Michael Pfreundschuh

Hartwig Pfreundschuh

Georg Pfreundschuh

Gerhard Pfreundschuh

 

Other publications of authors with the same name

Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia, , , , , , , , , and 3 other author(s). Blood, 117 (10): 2918–2923 (2011)Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL, , , , , , , , , and 3 other author(s). Blood, 104 (3): 634–641 (2004)Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL), , , , , , , , , and 5 other author(s). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 19 (3): 545–552 (2008)Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF, , , , , , , , , and 3 other author(s). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 12 (4): 471–477 (2001)CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group, , , , , , , , , and . Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 23 (5): 1267–1273 (2012)Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group, , , , , , , , , and . Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 (3): 580–586 (1994)Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma, , , , , , , , , and 1 other author(s). Clinical cancer research : an official journal of the American Association for Cancer Research, 18 (13): 3637–3647 (2012)The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL, , , , , , , , , and 5 other author(s). Blood, 119 (14): 3276–3284 (2012)The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab, , , , , and . Blood, 118 (17): 4657–4662 (2011)Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group, , , , , , , , , and . Blood, 116 (18): 3418–3425 (2010)